Skip to main content
Triangle logo TriangleGet started

Intensity modulated total marrow… (NCT06802315)

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS): a one-minute explainerNCT068023151 min

Intensity modulated total marrow irradiation trial for Acute Myeloid Leukemia, Relapsed, Adult (NCT06802315). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults aged eighteen to sixty-five with specified high-risk AML, MDS, or CML, eligible for a fully or partly mismatched donor stem-cell transplant.

The idea: marrow radiation joins fludarabine and busulfan conditioning before donor peripheral-blood stem cells. Radiation totals nine gray over three days. After transplant, cyclophosphamide, tacrolimus, and mycophenolate help prevent graft-versus-host disease. Researchers assess survival without relapse or graft-versus-host disease at one year, alongside safety and other outcomes.

This phase 2 study plans 38 patients. Matias Sanchez leads at UIC, Chicago, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.